SCHEMBL30677181

SCHEMBL30677181

NC(=O)C(CCC(=O)O)N1Cc2c(N)cccc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45
NFKB1 P19838 1/20 0.45
APEX1 P27695 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.39
ALOX15 P16050 3/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TSHR P16473 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501841 1.00 KDM4E (0.45) KDM4EALDH1A1POLBTP53GLA
SCHEMBL2169035 0.91 KDM4E (0.52) KDM4EALDH1A1POLBTP53GLA
SCHEMBL14506392 0.91 KDM4E (0.52) KDM4EALDH1A1POLBTP53GLA
SCHEMBL7850983 0.91 MEN1 (0.38) KDM4EALDH1A1POLBTP53GLA
SCHEMBL15247750 0.89 KDM4E (0.44) KDM4EALDH1A1POLBTP53GLA
SCHEMBL6368923 0.89 KDM4E (0.37) KDM4EALDH1A1POLBTP53GLA
SCHEMBL2257304 0.88 KDM4E (0.45) KDM4EALDH1A1POLBTP53GLA
SCHEMBL20425363 0.88 KDM4E (0.45) KDM4EALDH1A1POLBTP53GLA
SCHEMBL2169082 0.88 ALDH1A1 (0.40) KDM4EALDH1A1POLBHSD17B10L3MBTL1
SCHEMBL18747986 0.87 ALOX15 (0.36) KDM4EALDH1A1POLBTP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611798-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2025-09-10 EP disclosed
EP-4543923-A1 TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS Juno Therapeutics, Inc. (US) 2025-04-30 EP disclosed
CN-119546638-A Therapeutic methods for two-line therapy of CD19 targeted CAR T cells 朱诺治疗学股份有限公司 2025-02-28 CN disclosed
CN-118948892-A Combination of cell therapy with immunomodulatory compounds 朱诺治疗学股份有限公司 2024-11-15 CN disclosed
CN-118662614-A Articles and methods of treatment using adoptive cell therapy 朱诺治疗学股份有限公司 2024-09-20 CN disclosed
WO-2024097905-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2024-05-10 WO disclosed
CN-111225675-B Articles and methods of treatment using adoptive cell therapy 朱诺治疗学股份有限公司 2024-05-03 CN disclosed
WO-2023250400-A1 TREATMENT METHODS FOR SECOND LINE THERAPY OF CD19-TARGETED CAR T CELLS JUNO THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed